Skip to content
Facebook
  • DONATE NOW
  • JOIN CHM REGISTRY
CRFC Logo CRFC Logo

  • About CHM
    • What is Choroideremia?
    • Symptoms/Incidence
    • Inheritance
    • Cause/Treatment
    • Newly Diagnosed?
    • Patient Stories
    • Newsletter Sign-Up
    • Learn More
  • Who We Are
    • History
    • Board of Directors
    • Science Advisory Board
    • Press Releases
  • Medical Professionals
    • Free Genetic Testing
    • Clinical Trials
    • Research BioBank
    • Other Research Resources
    • Apply for Funding
  • Patients & Families
    • Join Patient Registry
    • Find a Doctor
    • Free Genetic Testing
    • Clinical Trials
    • CRF Membership
    • Support
    • Patient Toolkit
    • Resources
  • Research
    • Funded Research
    • CHM News
    • Clinical Trials
    • Evolving Therapies
    • Science Advisory Board
  • Get Involved
    • Join Team CHM
    • Host a Fundraiser
    • Become a Member
    • Join Patient Registry
    • Volunteer Opportunities
    • Events
  • Donate
    • Membership

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Productscurechm2019-08-28T17:46:09-05:00

Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trial

Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of NSR-REP1 in

Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trialcurechm2019-08-28T17:45:45-05:00

Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Study

Nightstar Therapeutics held it’s Initial Public Offering on Thursday September 28th, raising $75 Million which will be used to advance the company’s gene therapy

Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Studycurechm2019-08-28T17:45:57-05:00

Choroideremia Research Foundation Canada Inc.
16 Candlewood Drive
Brantford, ON N3R 6A1

(519) 758-0847
info@choroideremia.ca

Member of
Global Genes RARE Foundation Alliance member sealEveryLife Foundation member seal
© Copyright The Choroideremia Research Foundation Canada Inc. All Rights Reserved.   |   Disclaimer/Privacy
Skip to content
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Reset